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INTRODUCTION
Antigen processing and loading of peptides onto MHC class II molecules is a multistep process
that involves vesicular transport of the MHCII molecules along the secretory pathway, where
they eventually merge with antigen-containing endocytic vesicles or phagosomes (1). It is within
these late endosomal or lysosomal compartments that protein antigens become degraded by
proteases, most prominently by cathepsins, and where catalyzed peptide exchange by HLA-DM
fulfills its role in the efficient replacement of the invariant chain-derived peptide CLIP by
high-affinity pathogen- or host cell-derived peptides. Protease action may be limited by protein
antigen abundance and redox conditions, while HLA-DM is regulated at several stages, including
by expression levels, pH, or the co-expression of the competitive inhibitor HLA-DO. HLA-DM
activity leads to significant changes in the immunopeptidome of antigen-presenting cells, thereby
tailoring T cell responses and often shifting antigenicity toward high-affinity immunodominant
epitopes (2). Control of DM activity by DO has been described to be of prime importance in thymic
epithelial cells, in a subset of dendritic cells, and in B cells when entering the germinal centers
for affinity maturation and class switching (3, 4). In all of these cases, the switch from a broader,
self-peptide (CLIP) dominated immunopeptidome to a more focused repertoire is necessitated
by the requirement for more stringent antigen presentation, often preceding more intense T cell
reactivity and proliferation. Here, we review data on this cellular switch in the functionality of
antigen presentation and propose that it is promoted by an as yet poorly understood molecular
switch. Acknowledging that general biophysical parameters such as pH and redox are important
for antigen processing in general, an elusive DM-DO switch is postulated that would allow rapid
and strong shifts in immunopeptidomes. We capitalize on theoretical considerations to back our
opinion that a regulatable switch would have the advantage of allowing for a rapid and possibly
signal-dependent change in the peptide selection process, as might be required in the context of
rapidly changing immunological conditions.
REGULATION OF ANTIGEN PROCESSING
Proteolysis of antigens for MHC presentation and T cell surveillance, while certainly modulated
in its efficiency, is thought to constantly report on the proteome state of cells and organs in the
body. It is mostly viruses, bacteria, and cancer cells that have developed strategies to counter the
expression ofMHCI or the presentation of antigens byMHC class Imolecules, thereby tuning down
the corresponding MHCI immunopeptidomes. For MHC class II, the situation is more complex.
Presentation, in this case, is restricted to certain types of immune cells, andMHC class II expression
itself is regulated depending, e.g., on the maturation state of a certain cell type (1). Furthermore,
molecules associated with effective MHCII peptide presentation, such as cathepsins, the exchange
catalyst HLA-DM, or its inhibitor, HLA-DO, have been shown to be regulated in their expression
(4). Furthermore, the function of these proteins is pH-dependent, with an optimum of activity
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(e.g., for certain cathepsins or the exchange factor HLA-DM, the
pH optimum is close to the acidic pH of the late endosome). We
note that HLA-DM activity differs largely for MHCII allotypes
and thus that DM susceptibility can be truly defined only with
regard to a specific peptide-MHCII complex (5). For example,
in the mouse system it has been shown that the I-Ab or I-Ad
alleles are strongly dependent on the mouse homolog of HLA-
DM, H-2M, while the E-Ad and E-Ak variants are not (6, 7).
However, it seems that even for the latter variants, the exact
composition of the antigen repertoire can be modulated by H-
2M (7). Furthermore, for humans it has been found that several
variants of DM exist. Certain combinations of the α- and β-chain
of DM are expressed in the population, and the biochemical and
cellular properties of these DM proteins differ measurably with
regard to their activity and pH dependence and thus result in
distinct immunopeptidomes (8, 9).
It has been proposed that redox conditions within the
phagolysosomal and endolysosomal compartments are critical
for antigen presentation (10). Here, a balance has to be
maintained between rendering the cysteines of proteases in a
reduced, active form and not reducing the essential disulfide
bonds of other proteins as they are present, for example, in the
MHCII molecules themselves. This leaves the conundrum of how
certain antigens can be processed that are stabilized by disulfide
bonds but need to be reduced for efficient digestion by proteases.
It appears that enzymes, such as the gamma-interferon-inducible
lysosomal thioreductase (GILT), play an important role (11). For
example, it has been shown that reduction of the house dust mite
allergen Derp1 depends on GILT and that GILT thereby leads
to more efficient processing of the protein. Consequently, in a
mouse airway inflammation model of asthma, GILT knockout
mice exert mitigated allergic responses (12). Independent of
disulfide reduction, the foldedness of the birch pollen allergen
Betv1 along the endolysosomal pathway has been shown to
be critical for its immunogenicity (13), indicating that protein
stability is certainly one of the parameters that determine the
degradation kinetics of a protein and its subsequent loading onto
MHCIImolecules. The generally high thermodynamic stability of
long-lived MHCII-peptide complexes might be one reason why
they are largely protected from degradation themselves. However,
why the more instable MHCII allotypes such as certain HLA-DQ
variants are shielded from degradation is not clear; presumably
membrane partitioning and nanoscale localization within the late
endosome contribute to protecting them.
While the importance of pH, redox conditions, and protein
stability for antigen presentation is undisputed, these parameters
describe general biophysical properties that are not subject to
acute control. They rather shape the constitutive process of
presenting peptidomes on MHCII and may tune its general
features. Modulation of this constitutive MHCII pathway by
changes in the gene expression of its critical components
could impose long-term control that might be required, for
example, during the differentiation of dendritic cells or B cells.
However, the rapid switches of MHCII presentation induced
by antigen- or pathogen-related signals, such as those delivered
by Toll-like- or B-cell receptors (3), are unlikely to rely solely
on comparatively slow changes in gene expression (typically
requiring many hours to become manifest at protein level).
Hence, we hypothesize that a molecular switch, operating on
shorter “biochemical” time scales of minutes to hours, is involved
in the timely changes of the presented peptides. First, a cell
might signal strong receptor engagement in order to promote
the general turnover of antigen, thereby adjusting its presentation
properties to the new conditions. Thus, sustained exposure to
antigen would be distinguished from more serendipitous events
and result in a robust response that precedes irreversible fate
decisions. Molecular switches of this kind would typically operate
at the level of transport or proteolysis. Secondly, a molecular
switch could be engaged at the repertoire level, changing the
composition of the immunopeptidome and thereby directly
altering putative T cell responses. This type of switch could
comprise site-specific proteolytic events or modulators of the
peptide exchange process itself. In both cases, altered activity
might lead to a shift in the ratio of self-peptides to pathogen-
derived antigen and thus provide a means of rapidly modulating
the activation of T cells. In particular, regulation of the peptide
exchange process itself as the most downstream event in the
processing pathway seems to be well-suited to ultimately tuning
the presentation of antigen and stimulation of T cells.
CONTROL OF ANTIGEN EXCHANGE BY
HLA-DM
Antigen loading of MHC class II molecules is a process that
depends on the general features of endolysosomal processing
but also capitalizes on molecules uniquely evolved to enable
the highly efficient exchange of placeholder peptides against
exogenous, often pathogen-derived antigens in professional
antigen-presenting cells. The placeholders, termed class II-
associated invariant chain peptides, are derived from the
invariant chain (Ii or CD74) (14) as peptides of different
length displaying distinct properties (15, 16) and, for most
HLA allotypes, bind via the core sequence MRMATPLLM to
MHCII molecules. CLIP binding to human and mouse MHCII
molecules differs widely for individual allotypes (17), and several
mouse alleles (I-Ak, I-Ed, I-Ek) (6, 7), as well as human
allotypes (e.g., HLA-DQα1∗0501/DQβ1∗0301) (18, 19), show
poor CLIP binding, and thus peptide replacement takes place
efficiently even in the absence of H-2M/HLA-DM. However, the
exchange catalyst for these alleles still seems to be required to
stabilize unoccupied MHCII molecules or efficiently shape the
repertoire toward higher affinity peptides (7). Interestingly, the
CLIP sequence can bind in two flipped orientations along the
MHCII binding groove, with the equilibrium of the canonical
vs. inverted binding mode depending on the length of the
N- and C-terminal overhang regions, a process that itself is
catalyzed by HLA-DM (20, 21). In any event, the CLIP peptides
of HLA-DM/H-2M susceptible allotypes are replaced in the late
endosomal compartments by other peptides with similar or
higher affinity. Alternatively, if large concentrations of a non-
optimal antigen are provided, it might also be loaded onto
the MHCII molecule, simply based on the law of mass action.
However, since many MHCII-CLIP complexes, especially those
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of the HLA-DR locus, are already of high kinetic stability,
replacement rates are very low for these HLA allotypes and would
not proceed to a significant degree on a physiologically relevant
timescale (minutes-to-hours). The exchange catalyst HLA-DM,
which has its activity optimum at or near the acidic pH of the
late endosome, leads to more efficient exchange even for MHCII
allotypes that have low CLIP off-rates (2). Peptide exchange
occurs via rare conformation in the HLA molecules, which
occupy at most a few percent of the conformational ensemble
and are recognized by HLA-DM (22, 23). This mechanism
ensures that, for stable pMHCII complexes, the peptide can still
be replaced by higher affinity ligands within a time frame of
seconds to minutes. A simple mathematical model based on
experimentally determined exchange rates (22) shows how the
HLA-DM to HLA ratio controls the switching time (Figure 1).
A somewhat sub-stoichiometric ratio of DM:MHCII in the range
of 0.1–0.3 still enables switching times within the order of
minutes (Figure 1). Thus, the active concentration of the peptide
exchange catalyst HLA-DM controls switching time.
Indeed, the ratios of DM to MHCII in primary cells have been
reported to be quite variable and to depend on the differentiation
state of professional antigen-presenting cells (16). However, the
curve in Figure 1 also argues that the system does not need to
operate at a stoichiometric steady-state level for efficient catalysis,
leaving open the question to what extent expression levels
have to change in order to modulate the presented repertoire
significantly. Experimentally, it has been shown that a significant
minority of peptides and epitopes change when DM levels are
raised from low to high in a cellular model (2). In particular,
the amount of high affine peptides is fostered in the presence
of HLA-DM, a consequence that might be favorable in a certain
immunological context but undesired in others. Therefore,
regulation of DM activity is a key issue when considering




Biasing the repertoire of MHCII bound peptides toward high-
affinity ligands might be harmful or advantageous, depending
on the immunological context [reviewed in Alvaro-Benito et al.
(24)]. For example, it has been found that the absence of HLA-
DM in mice in the context of a type I diabetes model prevents
the animals from acquiring the disease (25), while, on the
other hand, DM seems to be required for constraining bacterial
pathogens such as Mycobacterium tuberculosis (26). Moreover,
DM expression in the thymus has been found to be low in the
cortical but high in the medullary epithelial cells of the thymus
(27), indicating that positive and negative selection have distinct
requirements for DM during T cell development. Apart from the
modulation of DM activity during these processes by regulation,
DM gene expression downregulation of HLA-DM can also be
achieved by co-expression of the DM competitive inhibitor
HLA-DO (DO). DO binds with much higher affinity to DM
than canonical MHCII molecules, thereby fully abrogating DM
exchange activity when present at stoichiometric concentrations
(28, 29). DO has also been suggested to have a direct
effect on classical MHC class II molecules by recognizing
a receptive conformation of the common allotype HLA-
DR1 (30), and it will be interesting to see whether the
underlying rare conformations can be detected directly by
experiment. More recently, a comprehensive immunopeptidome
study was performed comparing DO knockout and wild-type
human lymphoblastoid HLA-DR1 homozygous LG-2 cell lines,
extending previous studies on DM-independent peptide loading
(6, 7) and corroborating the finding that DO broadens the
repertoire, thereby counteracting the effect of DM to a certain
extent (4). How far such broadening of the repertoire plays a role
during certain phases of murine B cell development and dendritic
cell differentiation, two processes where DO expression is known
to be high, is an intriguing question. In human B cells, DO levels
are high only when B cell development in the bone marrow
is complete and are then downregulated in germinal centers,
where affinity maturation of B cells proceeds and where T/B cell
cooperation becomes of critical importance (31, 32). March9-
mediated ubiquitination is mostly thought to be responsible for
the reduced DO levels in GC B cells (33), but this leaves open the
question of how March9 activity is itself regulated. The DM-DO
complex is extremely stable and pH insensitive when investigated
in vitro (KD = 3.7 nM). However, once dissociated fromDM, DO
is rapidly inactivated at acidic pH, and an indirect influence of
acidification on DO stability along the endolysosomal pathway
has therefore been suggested (34).
The degradation rate of DO can be modeled based on
the KD of the complex. Assuming a typical kon for protein-
protein interactions of 105 M−1 s−1 (35), the calculated half-
time for complex dissociation is ∼30min. Assuming that each
dissociation event will translate into conformational changes
and subsequent degradation of the protein, this time represents
the lower limit for DO downregulation. In cells, there will
be some degree of competition between fast rebinding of
acutely dissociated DO to DM and DO degradation, so
that the effective half-life for DO is likely to be longer.
Indeed, in vitro studies showed that concentrations of free
DM and its associated exchange activity after preincubation
of DM:DO complexes at acidic pH were significant only
after 2 h and free DM was still increasing after 24 h when
analyzing loading of the hemagglutinin peptide HA in cellular
lysates (34). Thus, it seems that acidification alone would
lead to a slow, gradual, and non-reversible increase in
DM activity.
Rather than degradation of DO after slow release from a
tight complex with DM, the lowering of the effective DO-DM
affinity would provide a much faster means to release DM activity
from DO inhibition and, in turn, switch the HLA-presented
peptidome. Moreover, this switch would be reversible as long
as DO is present, enabling the system to adapt to changing
environmental stimuli. What is the evidence that such a switch
would be advantageous in vivo? There is no direct evidence yet
that the DM-DO complex is reversibly and rapidly switchable.
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FIGURE 1 | HLA-DM concentration controls the rate of peptide exchange at HLA. We modeled how rapid transitions in the conformational ensemble of HLA-peptide
are modulated by HLA-DM binding; HLA-DM stabilizes a rare active conformational state that facilitates peptide exchange [see Figure 1E in Wieczorek et al. (22)].
Based on the experimental data obtained from Wieczorek et al. (22), the modeling shows that HLA-DM concentration controls the switching time most strongly in the
substoichiometric regime.
However, circumstantial findings for adaptive changes in antigen
presentation exist where fast control of the DM:DO ratio would
be the most straightforward manipulatable parameter to change
the peptide repertoire. As mentioned before, DO expression is
seen in B cells first when they transition from the immature to
the mature state. These cells then enter the germinal centers,
and as earlier studies by Jensen and coworkers (32) showed,
stably express DO in the initial IgD+CD38− B cell population
that has not yet undergone affinity maturation. Interestingly,
GC B cells of the IgD−CD38+ type, which should consist
of centrocytes and centroblasts, downregulate DO (32). Since
these cells, especially the centrocytes in the light zone, are in
intense contact with follicular TFH cells, DO downregulation is
anticipated to unleash DM activity in order to allow the display
of high-affinity pMHCII complexes that are in turn prone to
engage more robustly in sustained T cell activation and thus
provide B cell help. Interestingly, a third GC B cell population,
namely IgD−CD38−, thought to represent memory cells, shows
robust DO expression levels. Thus, it is clear that interconverting
B cell populations exist that are under selective pressure to
encounter high-affinity antigen (36). While changing DO levels
reflect this requirement, it is likely that the genetic control is
supported by regulation at the protein level. Ubiquitination-
dependent degradation surely represents a possible regulatory
mechanism (33), but it has the disadvantage of being irreversible
and energetically costly. A reversible switch would, for example,
allow the individual GC B-cell populations to interconvert prior
to an irreversible fate decision. Moreover, when coupled to B cell
receptor activation, a more robust “two-signal” scenario could
be envisaged, where B cell receptor signaling by a higher affine
B cell receptor is intertwined with more persistent presentation
of a high-affinity pMHCII complex. There is experimental
evidence that DM interacts with endocytosed B cell receptor
in the late endosome (37), and it is thus not unlikely that
such a coupling exists. It will be important to test whether
the DM/Ig binding is altered in the presence of DO, since
this could indicate that the BCR could act as a switch itself
or at least contribute to a more acute response during B cell
antigen presentation.
What could be the nature of this switch? Is it possible that
a proteolytic event is coupled to such a switch in activity? It
is well-known, for example, that invariant chain processing is a
processive event where cleavage proceeds from the C-terminal to
the N-terminal end (38–40). In particular, Cathepsin-S is critical
for the production of the N-terminal fragments (41, 42) that
could in principle be involved in the appearance of peptides other
than CLIP and that may exert unanticipated functions through
binding to canonical or non-canonical MHCII molecules. The
fact that at least a partial MHCII binding groove exists in DO
makes it at least conceivable that a proteolytically cleaved peptide
binds to it (28).
This peptide would have been identified if it was constitutively
present or if several peptides could bind via anchor residues
as is the case for canonical MHCII molecules. Rather, this
peptide would be produced under certain conditions in a
switch-like manner that also allows its fast removal once DM
is bound again or when ubiquitination-mediated degradation
ensues. The proteolytic hypothesis, stating that inducible
cleavage of a protein fragment results in a competitive DO
binder, could be tested by applying selective inhibitors against,
for example, cathepsin S (43) and analyzing the amount
of free vs. bound HLA-DM. Alternatively, the spectrum of
post-translational modifications of free vs. DO-bound DM
molecules could be revisited, as there is ubiquitination,
phosphorylation, glycosylation, and lipid modification. Notably,
the DM α-chain contains a putative palmitoylation site in its
short cytoplasmic tail (44) that could serve as a signal in
changing the nanoscale localization of the molecule. Similarly,
glycosylation and phosphorylation sites have been identified
in the DO β-chain (45, 46). Capitalizing on modern, highly
sensitive mass spectrometers, previously unobserved changes
might be captured that are physiologically relevant and that
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could be validated by corresponding site-specific mutations.
Together with the option that Ig binding could also act
in a manner dependent on DM-DO complex-formation (37)
(see above), we thus present three experimentally testable
conditions to reinforce or disprove the suggestions made in this
opinion article.
Assuming the existence of such a molecular event, it
will quickly release inhibition of DM by DO and thus will
lead to a temporally regulatable activity of the exchange
catalyst. As the concentration of active DM not only controls
the speed of peptide exchange but also affects the affinity
range of presented peptides in an as yet poorly understood
manner (see above), such a molecular switch would be an
important regulator of the quality and quantity of antigen
presentation by MHCII. It is worth pointing out that antigen
recognition, at the T cell end of the interaction with the
APC, also employs an active molecular switch: T cells do
not simply sense the affinity of the interaction of peptide-
loaded MHC with the T cell receptor but rather employ
kinetic proofreading to discriminate between their agonists and
self-peptides (47, 48). Thus, in a conceptual framework, the
regulation of antigen presentation on the APC may not be
dissimilar from antigen recognition by T cells in employing active
molecular switches.
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